1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 13,200 | 13,600 | 09:30 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.03. | GH Research publishes phase 2b results for depression treatment | 3 | Investing.com | ||
| 25.03. | GH Research veröffentlicht positive Phase-2b-Studienergebnisse zu Depressionsmedikament | 2 | Investing.com Deutsch | ||
| 25.03. | GH Research PLC: GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD | 1 | GlobeNewswire (USA) | ||
| 25.03. | GH Research PLC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 16.03. | GH Research PLC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 10.03. | Guggenheim raises GH Research stock price target to $34 on trial data | 2 | Investing.com | ||
| 06.03. | GH Research: Needham erhöht Kursziel auf 32 $ im Vorfeld der Phase-3-Studie | 5 | Investing.com Deutsch | ||
| 06.03. | Needham raises GH Research stock price target to $32 on phase 3 plans | 1 | Investing.com | ||
| GH RESEARCH Aktie jetzt für 0€ handeln | |||||
| 06.03. | Citizens raises GH Research stock price target on phase 3 progress | 2 | Investing.com | ||
| 05.03. | GH Research GAAP EPS of -$0.79 | 1 | Seeking Alpha | ||
| 05.03. | GH Research PLC - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 05.03. | GH Research PLC - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| 05.03. | GH Research reports Phase 2b trial results for depression treatment | 1 | Investing.com | ||
| 05.03. | GH Research PLC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 22.01. | GH Research PLC - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 13.01. | GH Research PLC - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 06.01. | GH Research stock price target raised to $29 from $19 at Needham | 4 | Investing.com | ||
| 06.01. | GH Research: Aktie springt nach Aufhebung des FDA-Genehmigungsstopps - Canaccord erhöht Kursziel | 2 | Investing.com Deutsch | ||
| 06.01. | GH Research stock jumps as Canaccord raises price target on FDA hold lift | 2 | Investing.com | ||
| 06.01. | GH Research stock rises as FDA lifts clinical hold on GH001 | 5 | Investing.com |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 4,530 | +0,09 % | Aufgepasst! Riesiges Marktpotenzial im größten Teilbereich der Pharmabranche nutzen: mit Innovator Vidac Pharma, Platzhirsch Bayer oder Turnaround-Kandidat Evotec? | Die Onkologie ist der strategisch wichtigste Wachstumsmarkt der Pharmaindustrie und gleichzeitig einer der entscheidenden Hebel zur Verbesserung der globalen Gesundheit. Aktuell erkranken weltweit rund... ► Artikel lesen | |
| VALNEVA | 2,668 | -1,11 % | BRANDMELDUNG bei Valneva: 2,4% Plus und das könnte erst der Anfang sein - Was das für Ihr Depot bedeutet | ||
| BIOGEN | 147,04 | -0,28 % | Biogen to acquire Apellis in $5.6bn deal | ||
| BIOFRONTERA | 2,610 | +2,35 % | BIOFRONTERA AG im Abwärtsmodus - ruhige Einordnung | ||
| ILLUMINA | 102,88 | -0,23 % | Illumina Expands Collaboration With Labcorp To Advance Precision Oncology | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Wednesday announced an expanded collaboration with Labcorp to advance precision oncology through innovative applications of next-generation sequencing... ► Artikel lesen | |
| NANOREPRO | 1,455 | +2,83 % | Aktien KW 14 Trump spielt mit den Märkten - Kriegs-Ende oder nicht. News. Mutares. The Platform Group. Fortec. Norma Group. SUSS MicroTec. Pyramid. Nordex. NanoRepro. SFC Energy. 123fahrschule. Masterflex | Aktien - Immer noch Bomben auf den Iran. Trotz ansteigender Kritik und steigenden Preisen für die US-Wähler, Trump bleibt ratlos im Kampf. Am Mittwoch hofften alle auf die "Rede an die Nation". Am Ende... ► Artikel lesen | |
| OCUGEN | 1,524 | +1,74 % | Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,917 | +0,94 % | What's Going On With Inovio Pharmaceuticals Stock On Tuesday? | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,165 | +1,53 % | PacBio Announces the Appointment of Chris Gibson to the Board of Directors | MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher... ► Artikel lesen | |
| VAXART | 0,380 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 26.03.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 26.03.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 26.03.2026.ISIN NameCA2568277834 DOLLY... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,570 | +0,85 % | Arbutus Biopharma Corporation: Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update | Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025 $2.25B Moderna global settlement for infringement of lipid nanoparticle (LNP) delivery... ► Artikel lesen | |
| XOMA ROYALTY | 30,600 | +5,52 % | XOMA Royalty Corporation: XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements | Portfolio receipts: • Achieved over $50 million of cash receipts, including $33.6 million in royalties and $16.9 million milestones, in full year 2025 • Total receipts increased 9% with royalties... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,409 | +4,91 % | Cardiff Oncology, Inc.: Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth | Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive OfficerAppoints industry veterans Josh Muntner as Chief Financial Officer and Ajay Aggarwal, MD, MBA, as Chief... ► Artikel lesen | |
| CYTODYN | 0,236 | 0,00 % | CytoDyn Inc. - 10-Q, Quarterly Report | ||
| IMMUNIC | 0,992 | -0,80 % | EQS-News: Immunic AG: Immunic to Participate in Scientific and Medical Conferences in April | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Scientific and Medical Conferences in April
09.04.2026 / 12:30 CET/CEST
The issuer is solely responsible... ► Artikel lesen |
Das Unternehmen GH RESEARCH PLC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 13,600 Euro und damit +3,03 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GH RESEARCH PLC finden Sie auf Wallstreet Online.